Edge Therapeutics (EDGE) IPO Opens Modestly Higher
Get Alerts EDGE Hot Sheet
Join SI Premium – FREE
Today's IPO for Edge Therapeutics, Inc. (Nasdaq: EDGE) opened for trading at $11.60 after pricing 7,315,151 shares of its common stock at a public offering price of $11.00 per share, below the expected $14-$16 range. The IPO size was raised from 5.67 million.
Leerink Partners and Credit Suisse are acting as joint book-running managers for the offering. Guggenheim Securities and JMP Securities are acting as co-managers.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubrik IPO: 5 key things to know
- Rubrik (RBRK) Files for 23M Share IPO at $28-$31/sh
- JMP Securities Starts Reddit (RDDT) at Market Outperform, 'a Young Platform With Multiple Growth Levers'
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, JMP Securities, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!